Reporting of Tumour Deposits in Colorectal Cancer by Radiology and Pathology

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorImperial College London

About this trial

Recent research shows that tumour deposits-small spots of cancer found near the main bowel tumour-may give doctors important information about how aggressive the cancer is and how likely it is to come back.

Doctors can find tumour deposits either:

1. When looking at scans before surgery, or 2. when examining the removed bowel tissue under the microscope after surgery.

In the past, tumour deposits were not always recorded properly. This is because older cancer-staging systems (called TNM 5) used in the UK treated these spots differently, depending on their size, and sometimes labelled them as lymph nodes even when they were not. As a result, many tumour deposits were missed in reports.

Since 2018, the UK has been using an updated staging system (called TNM 8) that gives tumour deposits their own category. This means doctors are now expected to report them separately when they are found in the tissue around the bowel.

This matters because the investigators know that patients who have tumour deposits may have a higher risk of the cancer returning or spreading. Because of this, these patients might benefit from extra treatment-such as chemotherapy or radiotherapy-on top of surgery.

However, if tumour deposits are not routinely recorded on scans or pathology reports, doctors may not realise a patient has them. This means that:

1. Patients may not get the most appropriate advice about their cancer, and 2. Patients may miss out on treatments that could help reduce the chance of the cancer returning.

This research project aims to find out two things:

1. Are tumour deposits being routinely reported on scans and pathology reports for rectal cancer since the newer TNM 8 system was introduced? And 2. Is there a link between reporting tumour deposits and another important finding called EMVI (extramural vascular invasion), which also affects cancer behaviour and treatment decisions?

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Primary adenocarcinoma of the rectum (proven by biopsy)

Undergone surgical resection between 01st January 2007 to 31st December 2017 inclusive for the TNM 5 cohort

Undergone surgical resection between 01st January 2022 to 31st December 2024 inclusive for the TNM 8 cohort

Disqualifiers

Synchronous metastatic tumours

Under the age of 16 years

MRI and/or pathology reports are not available

Trial population

Patients (\>16 years old) with primary adenocarcinoma of the rectum who have undergone resectional surgery

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • No Intervention: Observational Cohort

    Other intervention

    No intervention is to be performed. This is an observational retrospective cohort study only

Treatment groups

225 Participants
are divided into 2 treatment groups
Group A: TNM51 intervention
Group B: TNM81 intervention

Trial outcomes

Primary outcomes

1

Frequency of Tumour Deposits

1. The frequency of Tumour Deposits on MRI in the TNM 8 cohort compared to TNM 5 cohort and 2. The frequency of Tumour Deposits on pathology in the TNM 8 cohort compared to TNM 5 cohort

Time frame
For MRI: MRI reporting within 8 weeks prior to surgery For pathology: Pathology reporting up to 4 weeks after surgery

Secondary outcomes

1

The correlation between reporting of tumour deposits and extramural venous invasion

1. The percentage of patients with extramural venous invasion on MRI among patients with MRI-detected tumour deposits. Measurement tool is standardised colorectal cancer pelvic MRI reporting. 2. The percentage of patients with histopathological extramural venous invasion among patients with histopathologically confirmed tumour deposits. Measurement tool is standardised colorectal cancer histopathology reporting.

Time frame
For MRI: MRI reporting within 8 weeks prior to surgery For pathology: Pathology reporting up to 4 weeks after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Imperial College London

Lead sponsor

Croydon Health Services NHS Trust

Collaborator

Epsom and St Helier University Hospitals NHS Trust

Collaborator

Basingstoke and North Hampshire Hospital

Collaborator

London North West University Health Care NHS Trust

Collaborator

This trial is not recruiting at the moment. You can still explore other options: